Intervention

WX-0593 Tablets

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5
Recruiting1
Common conditions4
Lead sponsors shown3
Advertisement

Clinical trials

5 shown
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung CancerNCT05765877 · 2023-03-01
RECRUITING
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLCNCT05351320 · 2022-04-30
UNKNOWN
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsNCT04632758 · 2019-06-01
UNKNOWN
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerNCT04641754 · 2019-03-07
UNKNOWN
A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor PatientsNCT03389815 · 2017-09-14
UNKNOWN

Trial status mix

UNKNOWN4
RECRUITING1

Phase mix

PHASE24
PHASE11
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.